Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jan;139(Pt 1):31-8.
doi: 10.1093/brain/awv342. Epub 2015 Dec 10.

Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome

Juan Darío Ortigoza-Escobar  1 , Marta Molero-Luis  2 , Angela Arias  3 , Alfonso Oyarzabal  4 , Niklas Darín  5 , Mercedes Serrano  6 , Angels Garcia-Cazorla  6 , Mireia Tondo  2 , María Hernández  2 , Judit Garcia-Villoria  3 , Mercedes Casado  7 , Laura Gort  3 , Johannes A Mayr  8 , Pilar Rodríguez-Pombo  9 , Antonia Ribes  3 , Rafael Artuch  7 , Belén Pérez-Dueñas  10
Affiliations
Clinical Trial

Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome

Juan Darío Ortigoza-Escobar et al. Brain. 2016 Jan.

Abstract

Thiamine transporter-2 deficiency is caused by mutations in the SLC19A3 gene. As opposed to other causes of Leigh syndrome, early administration of thiamine and biotin has a dramatic and immediate clinical effect. New biochemical markers are needed to aid in early diagnosis and timely therapeutic intervention. Thiamine derivatives were analysed by high performance liquid chromatography in 106 whole blood and 38 cerebrospinal fluid samples from paediatric controls, 16 cerebrospinal fluid samples from patients with Leigh syndrome, six of whom harboured mutations in the SLC19A3 gene, and 49 patients with other neurological disorders. Free-thiamine was remarkably reduced in the cerebrospinal fluid of five SLC19A3 patients before treatment. In contrast, free-thiamine was slightly decreased in 15.2% of patients with other neurological conditions, and above the reference range in one SLC19A3 patient on thiamine supplementation. We also observed a severe deficiency of free-thiamine and low levels of thiamine diphosphate in fibroblasts from SLC19A3 patients. Surprisingly, pyruvate dehydrogenase activity and mitochondrial substrate oxidation rates were within the control range. Thiamine derivatives normalized after the addition of thiamine to the culture medium. In conclusion, we found a profound deficiency of free-thiamine in the CSF and fibroblasts of patients with thiamine transporter-2 deficiency. Thiamine supplementation led to clinical improvement in patients early treated and restored thiamine values in fibroblasts and cerebrospinal fluid.

Keywords: Leigh syndrome; SLC19A3 gene; biotin thiamine responsive basal ganglia disease; mitochondrial disorders; striatal necrosis; thiamine transporter-2 deficiency.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms